Pregnidoxin

Quick links to important sections

Pregnidoxin

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pregnidoxin

Here is a quick overview of this common prescription medicine:

Property Description
Active Ingredients Doxylamine succinate and Pyridoxine hydrochloride (Vitamin B6)
Form Delayed-release tablets or capsules
Pharmacological Class Combination Antiemetic (Antihistamine + Vitamin)
Common Use Nausea and vomiting of pregnancy (NVP)
Status Prescription-only medicine (Rx)

Pregnidoxin is a brand name for a combination prescription medication used to treat nausea and vomiting of pregnancy (NVP), often called "morning sickness." It is intended for women whose symptoms have not improved after trying non-drug treatments, such as making specific dietary changes.

Composition and Features

This medicine contains two active ingredients: doxylamine succinate, an antihistamine, and pyridoxine hydrochloride, a form of Vitamin B6. These components work together and are clinically recognized for their antiemetic properties.

The specific delayed-release formulation of the tablet or capsule is a key feature of the brand. This design helps to control when the medicine is released in the body, which is important for providing effective relief, particularly during the morning hours when NVP symptoms often peak.

Medical Status

The combination of doxylamine and pyridoxine has been extensively studied and is widely supported by medical organizations. A comprehensive clinical review confirmed that this drug combination is both effective and the most studied treatment for NVP, leading to its status as a first-line pharmacological therapy.

Because of its intended use and active ingredients, the product is regulated as a prescription-only (Rx) medicine. Its regulatory approval for this indication further affirms its safety and effectiveness for use during pregnancy.

What side effects are possible with Pregnidoxin?

Possible Side Effects and Safety Information

Regulatory documents classify the potential adverse effects of Pregnidoxin based on their frequency and the body system affected. The most frequently reported adverse reactions are associated with Central Nervous System (CNS) effects and anticholinergic activity.

Adverse Reaction Classification

The table below summarizes common and uncommon side effects as documented in the drug’s official prescribing information:

Classification Representative Side Effects (Per Regulatory Documents)
Common (1% to 10%) Somnolence (drowsiness), Fatigue, Dry mouth
Uncommon (0.1% to 1%) Dizziness, Headache, Diarrhea, Urinary retention, Vision blurred

Somnolence is the most commonly reported adverse reaction and is noted in official labeling as being more prominent during the initial days of treatment.

Safety Considerations and Restrictions

The safety profile defines specific constraints and cautionary use, primarily related to the antihistamine component. The medicine is contraindicated in individuals with a known hypersensitivity to the ingredients or with concurrent use of Monoamine Oxidase Inhibitors (MAOIs), which can intensify certain effects.

Regulatory caution is also advised for patients with underlying conditions that may be exacerbated by anticholinergic effects, such as narrow-angle glaucoma or conditions causing obstruction in the gastrointestinal or urinary tract. Caution and potential dose adjustment are also noted for patients with Hepatic or Renal Impairment due to the potential for reduced drug clearance. The risk of Severe CNS Depression is explicitly highlighted when Pregnidoxin is used with alcohol or other CNS depressants.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Pregnidoxin (doxylamine succinate and pyridoxine hydrochloride) is strictly defined by the toxic effects of the doxylamine component, which exhibits anticholinergic properties. Overdose presents with documented signs that include restlessness, extreme drowsiness or sleepiness, mental confusion, dilated pupils, and a rapid heartbeat (tachycardia).


Severe and Life-Threatening Outcomes

Regulatory documents state that at toxic doses, overdose can escalate to severe and life-threatening complications, including seizures, rhabdomyolysis, acute renal failure, and cardiorespiratory arrest.


Emergency Action Required

If an overdose is suspected, seek emergency medical attention immediately. Users must call the Poison Help line or emergency services if severe symptoms occur, such as trouble breathing, collapse, or a seizure. Due to the delayed-release formulation, the signs of toxicity may not be apparent immediately, necessitating prolonged observation. Management procedures outlined by regulatory authorities involve general supportive care, such as gastric lavage or administration of activated charcoal, as no specific antidote is available.


Population-Specific Note

Official labeling specifically notes that the pediatric population appears to be at a high risk for cardiorespiratory arrest and fatalities following doxylamine overdose.

Therapeutic Uses of Pregnidoxin

What Pregnidoxin Treats: Main Uses and Benefits

Pregnidoxin is commonly used to help with Nausea and Vomiting of Pregnancy (NVP), applied across domains where additional symptomatic support is needed. It is relevant for managing symptoms related to persistent sickness and recurrent vomiting that have not responded to conservative management. This is relevant in situations where symptoms may intensify temporarily or are not managed by initial, non-drug interventions. The clinical application of this specific antiemetic combination is consistent with common practice guidance.

The primary therapeutic benefit is to provide support that helps ease the overall symptom burden in pregnant women experiencing NVP. Its use is relevant in conditions characterized by periods of heightened symptoms, such as symptoms that interfere with daily comfort and episodic manifestations. By managing symptoms that interfere with daily comfort, it contributes to easing the overall symptom load and supports improved day-to-day comfort during symptomatic periods. It assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations.


Quick Fact: Relevant for Easing Persistent Nausea

Eligibility and Restrictions for Use

Who Can and Cannot Use Pregnidoxin?

The population eligibility for Pregnidoxin (Doxylamine succinate and Pyridoxine hydrochloride) is strictly defined by regulatory documents, distinguishing between approved use, contraindications, and populations requiring caution.

Approved Use and Contraindications

Classification Population Status
Allowed Use Pregnant women with nausea and vomiting of pregnancy (NVP) who have not responded to conservative management.
Contraindicated Patients with known hypersensitivity to doxylamine, pyridoxine, or other ethanolamine antihistamines. Patients concurrently taking Monoamine Oxidase (MAO) inhibitors.

Population Limitations and Restrictions

Restriction Category Regulatory Status
Age-Related Pediatric (Under 18): Safety and effectiveness have not been established. Geriatric: No information is available on the effects of the combination.
Physiological Status Breastfeeding: Not recommended as the antihistamine component may pass into breast milk.
Conditional Use Use with caution is required for patients with narrow angle glaucoma, increased intraocular pressure, stenosing peptic ulcer, or urinary/pyloroduodenal obstruction due to anticholinergic effects.
Limitation of Use Hyperemesis Gravidarum is an explicit limitation; the medicine has not been studied in this severe population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pregnidoxin, containing doxylamine succinate and pyridoxine hydrochloride, has officially documented interaction patterns that are classified based on regulatory guidance.

Pharmacodynamic and Contraindicated Interactions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated in prescribing information. This restriction is due to MAOIs intensifying and prolonging the adverse central nervous system (CNS) effects of the doxylamine component.

The concurrent use of Pregnidoxin with other CNS Depressants (including tranquilizers, hypnotic sedatives, and alcohol) is officially not recommended. This restriction stems from a documented additive pharmacodynamic effect, which can lead to severe drowsiness or somnolence.

Pharmacokinetic and Population-Specific Interactions

Drug-Food Interaction

The absorption of this delayed-release medication is significantly affected by food. Regulatory documents state that consuming food with the tablets delays the onset of action and reduces the absorption of the active ingredients. This pharmacokinetic interaction dictates that the medicine should be taken on an empty stomach to ensure optimal and timely delivery.

Population Considerations

Caution is advised in patients with hepatic or renal impairment. Official regulatory texts note that the metabolism and excretion of doxylamine and pyridoxine may theoretically be reduced in these populations, which could potentially lead to increased drug exposure and altered effects.

Mechanism of Action

Pregnidoxin is a fixed-dose combination containing doxylamine succinate and pyridoxine hydrochloride. Doxylamine, a first-generation antihistamine, is highly lipophilic, enabling its diffusion across the blood-brain barrier. Its primary biological target is the central and peripheral Histamine H1 receptor, where it functions as a competitive antagonist. This action inhibits histaminergic neurotransmission, specifically reducing the signaling input to the vomiting center located in the medulla oblongata, a key component of the emetic reflex pathway.

Pyridoxine (Vitamin B6) functions as a precursor that is metabolized primarily in the liver to the coenzyme pyridoxal 5-phosphate (PLP). PLP is an essential cofactor for numerous enzymatic reactions, including the synthesis and catabolism of multiple neurotransmitters, such as serotonin (5-HT) and dopamine. The systemic physiological consequence of the combined pharmacodynamic activity is a modulation of central pathways controlling the emetic response.

Dosage and Administration Information

How Pregnidoxin is Used

Pregnidoxin is a prescription medication used orally, adhering to a specific, stepped dosing protocol. The medicine is supplied as a delayed-release tablet or capsule containing 10 mg of doxylamine succinate and 10 mg of pyridoxine hydrochloride.

Administration Requirements

To ensure the delayed-release mechanism functions correctly, specific administration rules must be followed:

  • Route: Oral use only.
  • Handling: The tablets/capsules must be swallowed whole. They should never be crushed, chewed, or split.
  • Timing: The initial dose must be taken at bedtime on an empty stomach with water.

Official Dosing Schedule

Dosage begins with a set amount and is adjusted based on individual needs, following a daily titration schedule up to a maximum dose of four tablets per day (40 mg/40 mg total).

Dosing Step Total Daily Tablets Timing
Initial Dose Two tablets (20 mg/20 mg) At bedtime
If Symptoms Persist Three tablets One in the morning, two at bedtime
Maximum Dose Four tablets (40 mg/40 mg) One in the morning, one mid-afternoon, two at bedtime

If a dose is missed, it is instructed that the patient should take the next scheduled dose at the usual time and should not double the dose. The need for continued therapy should be periodically assessed by a healthcare professional.

Recent Clinical Evidence

Research evidence / Overview of studies for Pregnidoxin (Doxylamine/Pyridoxine)

Evidence for Use in Moderate Nausea and Vomiting of Pregnancy (NVP)

Research exploring how symptoms change over time has primarily focused on the combination of doxylamine and pyridoxine for pregnant women experiencing moderate NVP that remained present after trying initial changes to diet or lifestyle. The primary research applied in studies examining patient-reported experiences includes short-term, placebo-controlled Randomized Controlled Trials (RCTs). These trials monitor responses over defined time intervals and compare the results of the drug combination against an inactive substance (a placebo).

These studies used a specific method to measure outcomes related to physical discomfort: the Pregnancy-Unique Quantification of Emesis (PUQE) score. This score is relevant in evidence describing how symptoms are measured, as it tracks three separate components: the severity of nausea, the number of vomiting episodes, and the amount of retching. Studies monitored how symptoms evolved in the observed populations, typically pregnant women in their first trimester (around 7 to 14 weeks). Findings describe patterns observed in the studies where a change in the PUQE score was recorded during the short-term study period compared to the group receiving the placebo.

Long-Term Research and Evidence Gaps

Research indicates that the primary evidence is based on a short follow-up duration, with the main symptom measurements taken after about two weeks of study. This means there is limited information for long-term outcomes or how the symptoms evolved over the entire duration of a woman’s pregnancy. Also, the research examined women with moderate symptoms, and data for certain groups remain insufficient.

Specifically, the main research examined does not provide sufficient data on women with the most severe form of sickness, Hyperemesis Gravidarum (HG). The measured difference between the active drug combination and the placebo was acknowledged as small on the validated symptom scale. Research provides context but not individual predictions regarding how symptoms present throughout pregnancy.

Frequently Asked Questions (FAQ)

Common questions about Pregnidoxin (FAQ)


Q: Is Pregnidoxin the same thing as B6 vitamins?

According to the official product information, Pregnidoxin is a fixed-dose combination medicine. It contains two active ingredients: doxylamine succinate, which is an antihistamine, and pyridoxine hydrochloride, which is a form of Vitamin B6. Therefore, it is not simply Vitamin B6 alone.


Q: How long does it typically take for Pregnidoxin to start working?

Official labeling describes this medication as a delayed-release product. This specific formulation helps to control when the active ingredients are released into the body. Regulatory documents also state that the onset of action is delayed if the tablets or capsules are taken at the same time as food.


Q: Are there any common over-the-counter medications that interact with Pregnidoxin?

Regulatory documents include a general warning regarding concurrent use with other central nervous system (CNS) depressants. This class of medicine can include certain over-the-counter cold, cough, or allergy products. Using them together may lead to an increased risk of somnolence, which means increased sleepiness or drowsiness.


Q: Is there a generic version of Pregnidoxin available?

Regulatory records show that the active ingredients in Pregnidoxin are available in both brand-name and generic formulations. These generic versions are reviewed by regulatory bodies and deemed to be therapeutically equivalent to the brand-name product.


Q: Can men use Pregnidoxin for any medical purpose?

According to official product labeling, the approved indication for Pregnidoxin is limited to the treatment of nausea and vomiting of pregnancy (NVP). This medicine is indicated for use only in pregnant women whose symptoms have not responded to initial non-drug management.


Q: Does Pregnidoxin interact with herbal supplements like ginger or chamomile?

Official guidance advises patients to inform their healthcare professional about all products they are using. This includes prescription and non-prescription medicines, as well as any vitamins, minerals, and herbal supplements.


Q: Are there long-term side effects associated with Pregnidoxin use?

Studies examining the use of this medicine have primarily focused on short-term follow-up periods. Consequently, official research summaries state that there is limited information available regarding outcomes for patients who use the medicine over the entire duration of their pregnancy.


Q: Can I take other vitamins while I am using Pregnidoxin?

Official guidance advises patients to inform their healthcare professional about all products they are using. This includes prescription and non-prescription medicines, as well as any vitamins, minerals, and herbal supplements.


Q: What should I do if the medicine does not seem to be working?

Official guidance states that if symptoms persist or become more severe despite following the administration protocol, the patient should consult a healthcare professional. This is advised so the need for continued therapy can be reevaluated.


Q: How does the effectiveness of Pregnidoxin compare to lifestyle changes alone?

Official information describes Pregnidoxin as a treatment for nausea and vomiting of pregnancy (NVP) when symptoms persist after conservative management. Conservative management typically includes non-drug treatments like making specific dietary or lifestyle changes.


Q: Do studies suggest Pregnidoxin has any impact on fetal development?

Regulatory reviews of this combination medicine state that its use during pregnancy is not associated with an increased risk of birth defects or teratogenicity. This finding is supported by numerous studies and meta-analyses.


Q: If I have a history of depression, can I still take Pregnidoxin?

Official warnings advise that caution is needed when prescribing the medication to patients with a history of depression or other psychiatric disorders. This is due to the antihistamine component and its effects on the central nervous system. Regulatory guidance directs that patients be monitored for any changes in mood or behavior.


Q: Does Pregnidoxin contain gluten or common allergens?

Official patient labeling provides a complete list of both the active and inactive ingredients in the formulation. Official guidance indicates the medicine is contraindicated for individuals with a known hypersensitivity to any ingredient in the formulation.


Q: Can stopping Pregnidoxin suddenly cause any issues?

Regulatory guidance advises that sudden discontinuation of the treatment may result in the return or worsening of the symptoms being managed. The medicine should only be stopped as directed by a healthcare professional.


Q: Are there any known side effects on mood or mental clarity?

Adverse reaction reports describe nervous system effects such as dizziness and headache, which can impact mental clarity. They also list certain psychiatric disorders, including anxiety, disorientation, insomnia, and nightmares.


Q: What are the rules regarding driving or operating machinery while taking Pregnidoxin?

Official warnings caution patients to avoid activities that require complete mental alertness, such as driving or operating heavy machinery. This caution is due to the risk of somnolence (drowsiness), which is the most commonly reported adverse reaction. Patients are advised to wait until they know how the medicine affects them.


Q: What are the physical characteristics of the Pregnidoxin tablet or capsule?

Official product labeling provides a description of the medicine's dosage form and strength. This description includes the physical characteristics such as the color, shape, and the imprinting found on the tablets or capsules.


Q: Are there specific laboratory tests that can be affected by taking Pregnidoxin?

Regulatory warnings indicate that using this medicine may interfere with the results of certain urine screening tests. This includes tests for substances such as methadone, opiates, and Phencyclidine Phosphate (PCP).


Q: What countries is Pregnidoxin approved for use in?

The combination has been approved by regulatory agencies in multiple jurisdictions for the treatment of NVP. For example, it is approved by the U.S. Food and Drug Administration (FDA) for the treatment of nausea and vomiting of pregnancy.


Q: Does Pregnidoxin have a risk of addiction or dependence?

Official regulatory documents classify this medicine as having no known risk of addiction or dependence.


Q: How does the body typically eliminate Pregnidoxin?

Official pharmacokinetics information describes how the medicine is processed by the body. The active ingredients are primarily eliminated through a process called metabolism and subsequently excreted in the urine.


Q: What is the main difference between Pregnidoxin and doxylamine?

Pregnidoxin is a fixed-dose combination product containing two active ingredients. It contains the antihistamine doxylamine succinate along with pyridoxine hydrochloride, which is a form of Vitamin B6.

How should Pregnidoxin be stored and disposed of?

Pregnidoxin (doxylamine succinate and pyridoxine hydrochloride) must be stored and disposed of according to the official specifications defined in regulatory labeling.

Storage Conditions

Requirement Specification
Temperature Controlled Room Temperature: 20 C to 25 C (68 F to 77 F)
Protection Keep from freezing; avoid excess heat and moisture.
Container Store in the original container and keep the cap tightly closed.
Child Safety Must be kept out of the reach of children.

Disposal Instructions

Unused or expired medication should be discarded according to local regulations. Official guidance recommends utilizing community drug take-back programs whenever possible. If these programs are unavailable, unused tablets can be safely disposed of in the household trash after being mixed with an undesirable substance (such as coffee grounds or dirt) and placed into a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pregnidoxin found in:

A-Z Index: